Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaPivotal data from the first phase 3 study of a BTKi in immune ...
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia
Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the ...
BioSpace12d
Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win
Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved ...
Morningstar13d
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with ...
Nasdaq13d
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia
(RTTNews) - Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in ...
ADVFN13d
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of ...
Yahoo Finance13d
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or ...